Combining Antiplatelet Drugs and Oral Anticoagulant Therapy in Atrial Fibrillation: Acute Coronary Syndromes and/or Percutaneous Coronary Intervention/Stenting Revisited
Author(s) -
Timothy Watson,
Gregory Y.H. Lip
Publication year - 2007
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.107.492488
Subject(s) - medicine , percutaneous coronary intervention , atrial fibrillation , acute coronary syndrome , aspirin , cardiology , clopidogrel , coronary artery disease , angioplasty , myocardial infarction
To the Editor:We agree with Gorelick1 that there is little evidence that combination aspirin and oral anticoagulant (OAC) therapy among patients with atrial fibrillation (AF) improves stroke prevention but, instead, increases risk of major bleeding. The latter should come as little surprise, given the mode of action of both drugs.Indeed, the efficacy of OAC compared with aspirin in this condition is overwhelmingly supported by data from clinical trials.2 However, AF commonly associates with (cardio)vascular disease, and frequently AF patients are still prescribed both OAC and antiplatelet therapies in combination. In the setting of …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom